AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 55.7% in April

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 248,631 shares, a growth of 55.7% from the March 31st total of 159,719 shares. Based on an average daily trading volume, of 335,566 shares, the short-interest ratio is presently 0.7 days. Approximately 3.1% of the company’s stock are short sold.

AIM ImmunoTech Trading Up 0.8%

AIM stock traded up $0.00 during midday trading on Wednesday, hitting $0.52. The company’s stock had a trading volume of 64,830 shares, compared to its average volume of 3,525,623. The company has a market cap of $4.27 million, a PE ratio of -0.05 and a beta of 1.36. AIM ImmunoTech has a 12 month low of $0.48 and a 12 month high of $20.35. The firm’s 50-day moving average is $0.72 and its 200-day moving average is $1.24.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.45) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million during the quarter. Analysts expect that AIM ImmunoTech will post -4.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Hedge Funds Weigh In On AIM ImmunoTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sabby Management LLC bought a new stake in AIM ImmunoTech in the 3rd quarter worth approximately $79,000. DRW Securities LLC grew its position in AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in AIM ImmunoTech in the 2nd quarter worth approximately $87,000. 12.02% of the stock is owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.